| Product | Ursodeoxycholic Acid (UDCA) |
|---|---|
| CAS | 128-13-2 |
| Primary Pharmacopoeias | USP, EP, BP, JP, IP |
| USP Assay Range | 98.0-102.0% |
| EP Assay Range | 99.0-101.0% |
| Key EP Impurity (CDCA) | ≤ 0.10% |
| Key EP Impurity (LCA) | ≤ 0.15% |
| Residual Solvent Standard | ICH Q3C |
Pharmaceutical-grade ursodeoxycholic acid (UDCA) API is supplied against pharmacopoeia monographs that define identity, purity, and quality specifications. Below is a side-by-side comparison of the USP and EP monographs for UDCA, plus guidance on reading a Certificate of Analysis (CoA) and the regulatory certifications required for market access in the United States and Europe.
The United States Pharmacopeia (USP) monograph for Ursodeoxycholic Acid establishes the legally recognized quality standard for UDCA API marketed in the United States. The current USP monograph specifies the following key quality parameters:
Identification is confirmed by infrared (IR) absorption spectrophotometry compared with a USP reference standard. The IR spectrum of the test sample must exhibit maxima at the same wavelengths as the USP Ursodeoxycholic Acid RS. Also, the retention time of the major peak in the assay chromatogram must correspond to that of the reference standard.
The USP assay for UDCA is performed by HPLC. On the anhydrous basis, UDCA must contain 98.0-102.0% of C24H40O4.
Related substances are determined by HPLC. Individual specified impurities (including chenodeoxycholic acid) are limited to NMT 0.5% each. Total impurities must not exceed 2.0%. This is notably less stringent than the EP limits.
Specific rotation: +58.0° to +62.0° (determined on a 20 mg/mL solution in ethanol at 20°C).. Loss on drying: ≤ 1.0% (determined at 105°C for 2 hours).. Heavy metals: ≤ 20 ppm (Method II).. Residual solvents: Must comply with USP <467> Residual Solvents, which implements ICH Q3C..
The European Pharmacopoeia (Ph. Eur.) monograph for Ursodeoxycholic Acid (monograph 1275) sets the quality standard for UDCA API in EU member states and countries that adopt the Ph. Eur. The EP monograph is more demanding in its impurity specifications than the USP monograph.
Identification is confirmed by IR spectrophotometry (matching the EP reference standard), by specific optical rotation, and by thin-layer chromatography (TLC) as an additional confirmatory test.
UDCA must contain 99.0-101.0% of C24H40O4 on the anhydrous basis by potentiometric titration with 0.1M tetrabutylammonium hydroxide. This narrower range reflects the higher purity expectation for the European market.
The EP monograph is more rigorous in its impurity specifications. The following limits reflect the EP monograph supplemented by typical CEP-holder product specifications [citation needed]:
Chenodeoxycholic acid (CDCA): ≤ 0.10% (impurity A; critical process-related impurity from incomplete epimerization). Lithocholic acid (LCA): ≤ 0.15% (impurity B; potentially hepatotoxic monohydroxy bile acid). Any other individual impurity: ≤ 0.10%. Total impurities: ≤ 0.5%. Disregard limit: 0.05%.
The EP's impurity specification is approximately four times tighter than the USP specification for total impurities (0.5% vs 2.0%). An API that passes USP may not meet EP requirements solely on the basis of the impurity profile.
Specific rotation: +58.0° to +62.0° (anhydrous basis).. Loss on drying: ≤ 1.0% (determined at 100-105°C).. Heavy metals: ≤ 20 ppm (Method A).. Residual solvents: Must comply with ICH Q3C. Ethanol is specifically limited to ≤ 5000 ppm, reflecting its use as a recrystallization solvent in UDCA manufacturing.. Acidity / Alkalinity: The solution must not require more than 0.1 mL of 0.01M HCl or 0.01M NaOH for neutralization..
| Parameter | USP | EP (Ph. Eur.) | Stricter Standard |
|---|---|---|---|
| Assay (anhydrous basis) | 98.0-102.0% | 99.0-101.0% | EP |
| Assay method | HPLC | Potentiometric titration | ; |
| CDCA (Impurity A) | ≤ 0.5% (as individual impurity) | ≤ 0.10% | EP |
| LCA (Impurity B) | ≤ 0.5% (as individual impurity) | ≤ 0.15% | EP |
| Any other individual impurity | ≤ 0.5% | ≤ 0.10% | EP |
| Total impurities | ≤ 2.0% | ≤ 0.5% | EP |
| Specific rotation | +58.0° to +62.0° | +58.0° to +62.0° (anhydrous) | Equivalent |
| Loss on drying | ≤ 1.0% | ≤ 1.0% | Equivalent |
| Heavy metals | ≤ 20 ppm (Method II) | ≤ 20 ppm (Method A) | Equivalent |
| Residual solvents | ICH Q3C (USP <467>) | ICH Q3C (Ethanol ≤ 5000 ppm) | EP (specifies ethanol limit) |
| Microbial limits | USP <61>/<62> | TAMC ≤ 1000 CFU/g; TYMC ≤ 100 CFU/g | Equivalent in practice |
| Acidity/Alkalinity | Not specified | Specified | EP |
High-performance liquid chromatography (HPLC) is the primary analytical technique for UDCA purity and impurity profiling. A typical UDCA HPLC method uses a C18 reversed-phase column with a mobile phase consisting of acetonitrile and phosphate buffer or formic acid buffer at controlled pH, with UV detection at 200-210 nm or refractive index detection. The USP and EP methods differ in column specifications, mobile phase composition, and gradient profile, so method equivalency must be verified when comparing results across pharmacopoeias.
UDCA is typically purified by recrystallization from ethanol, which is a Class 3 solvent under ICH Q3C (low toxic potential). Ethanol residual levels in well-manufactured UDCA are typically well below the 5000 ppm EP limit. Other potential residual solvents from the synthetic route (e.g., toluene, methanol, acetone) must also be controlled. Compliance with ICH Q3C is verified by gas chromatography with headspace sampling (GC-HS).
UDCA contains multiple chiral centers in its steroid nucleus (specifically at positions 3, 5, 7, 20) and the specific rotation measurement confirms stereochemical integrity. For UDCA, the specific rotation of +58.0° to +62.0° distinguishes it from chenodeoxycholic acid (+11° to +13°) and cholic acid (+35° to +39°). A specific rotation outside the monograph range may indicate contamination with another bile acid epimer.
Traditional heavy metals testing (≤ 20 ppm as lead) provides a non-specific screen. For markets adopting ICH Q3D (Guideline for Elemental Impurities), manufacturers may need to demonstrate compliance for specific elemental impurities (Class 1, 2A, 2B, and 3) relevant to the UDCA production process and equipment. Catalytic metals used in the epimerization step (if any) require particular attention.
A properly structured UDCA CoA provides a batch-specific quality report. Quality assurance professionals and procurement specialists reviewing a UDCA CoA should focus on these sections in order of priority:
| COA Section | What to Look For | Red Flag |
|---|---|---|
| Product Name & CAS | "Ursodeoxycholic Acid" with CAS 128-13-2. Verify the pharmacopoeia grade (USP/EP) is stated. | Product described as "UDCA powder" without pharmacopoeia reference. |
| Batch Number | Unique alphanumeric code. Cross-reference with packaging label and shipping documents. | Batch number format inconsistent with previous batches from same supplier. |
| Manufacturing Date | Should be within the last 12 months. Older material may have reduced retest period remaining. | Manufacturing date older than 24 months with no stability extension data. |
| Retest / Expiry Date | Typically 3-5 years from manufacturing date for UDCA stored at room temperature, protected from moisture. | Retest period unusually short (under 2 years) — may indicate stability concerns. |
| Assay (HPLC) | EP: 99.0-101.0% | USP: 98.0-102.0%. Value should be near the center of the range. | Assay at the extreme low end of the acceptable range — may indicate degradation or incomplete purification. |
| CDCA Content | EP: ≤0.10%. This is the primary process impurity — the most discriminating quality indicator for UDCA. | CDCA level above 0.08% and trending upward — epimerization process may be drifting. |
| Lithocholic Acid | EP: ≤0.15%. LCA is hepatotoxic; this limit has direct safety significance. | LCA detected at any level above 0.10% without investigation into the purification process. |
| Residual Solvents | Ethanol ≤5,000 ppm per EP monograph. Other Class 2 solvents below ICH Q3C limits. | Unidentified solvent peak on GC chromatogram — may indicate an uncontrolled process solvent. |
| Specific Rotation | +58.0° to +62.0° (anhydrous basis). Confirms stereochemical integrity. | Value outside range — may indicate contamination with another bile acid epimer or incorrect drying. |
| Approval | Dated signature from QC/QA manager, with quality unit stamp or electronic equivalent. | Unsigned, undated, or signed by a commercial/sales department employee. |
A Certificate of Suitability to the Monographs of the European Pharmacopoeia (CEP) is the most important certification for UDCA API entering the European market. A CEP is granted by the EDQM after a technical assessment of the manufacturer's submission and an on-site GMP inspection.
The CEP certifies that the manufacturer's UDCA production process, quality control, and impurity profile are adequately controlled by the EP monograph. For a marketing authorization holder (MAH) filing a drug product using UDCA as the API, referencing a valid CEP simplifies the dossier because the MAH does not need to provide the full API quality section, the CEP is accepted as proof of compliance.
CEP validity should be verified through the EDQM Certification Database before purchasing. A CEP can be voluntarily withdrawn, suspended by EDQM, or revoked — a previously valid CEP number does not guarantee current validity. For definitions of relevant terms, see our regulatory glossary.
For manufacturers seeking a first-time CEP for UDCA, the process follows five stages. For buyers evaluating a supplier, understanding this timeline explains why CEP-holding manufacturers command a premium:
| Stage | Action | Typical Timeline |
|---|---|---|
| 1. Pre-Submission | Prepare the CEP dossier (Module 3 format): manufacturing process description, impurity profile and discussion, analytical method validation, specifications, batch analysis data (at least two production batches), stability data, and GMP compliance declaration. Submitted electronically through the EDQM Common European Submission Platform (CESP). | 3-6 months preparation |
| 2. Technical Assessment | EDQM assessors review the dossier for scientific completeness and compliance with the EP monograph. If deficiencies are found, a Request for Additional Information (RAI) is issued with a response deadline (typically 1-3 months). Multiple rounds of questions are possible before the dossier is deemed adequate. | 4-8 months |
| 3. GMP Inspection | EDQM commissions a GMP inspection of the manufacturing site through the relevant competent authority. The inspection verifies compliance with EU GMP Part II (ICH Q7 for APIs). Inspection findings must be resolved before the CEP can be granted. This stage carries the highest risk of delay. | 2-6 months (scheduling + follow-up) |
| 4. CEP Grant | Upon successful technical assessment and GMP inspection, EDQM issues the Certificate of Suitability. The CEP is published in the EDQM Certification Database and becomes valid for use in EU marketing authorization applications. | 1-2 months after inspection close-out |
| 5. Maintenance | CEP holders must: notify EDQM of any changes to the manufacturing process or site (revision/renewal application), undergo periodic GMP re-inspections (typically every 2-3 years), and renew the CEP every 5 years. Failure to maintain these obligations results in suspension or withdrawal. | Ongoing |
Total timeline from dossier preparation to CEP grant: typically 12-18 months. For buyers, this means a supplier with an active, maintained CEP has completed a rigorous, multi-year regulatory process — the CEP is not a one-time certificate but evidence of an ongoing regulatory relationship with EDQM.
GMP (Good Manufacturing Practice) compliance underlies every aspect of UDCA API quality. For the US market, GMP compliance is verified by FDA inspection of the manufacturing facility. For the EU market, GMP compliance is verified by EDQM inspection (for CEP holders) or by a competent authority of an EU member state.
Key GMP requirements specific to UDCA manufacturing include: (1) documented process validation demonstrating that the epimerization and purification steps consistently produce material meeting the claimed pharmacopoeia specification; (2) cleaning validation for multi-purpose equipment used for steroid APIs, with limits that control cross-contamination risk to acceptable levels; (3) a stability program providing real-time and accelerated stability data supporting the assigned retest period; and (4) an ongoing Annual Product Quality Review (APQR) that trends quality attributes across batches, identifies adverse trends, and triggers preventive actions where necessary.